Forms 8-K

20.06.2008

Company News

Sangui BioTech files three 2007 quarterly reports, sales increased, losses continue

Witten, Germany, June 20, 2008 - Sangui BioTech International, Inc., has now filed its quarterly reports on Form 10QSB with the SEC covering the quarters ended September 30, 2006; December 31, 2006, and March 31, 2007. In the first nine month of its 2007 financial year the company generated sales of approximately USD 345,000 as compared to approximately USD 95,000 in the first nine months of FY 2006. Operating expenses amounted to almost USD 600,000. The increase as compared to the USD 356,000 in the previous year period is due to increased efforts to expand operations to international markets. The company incurred a net loss of approximately USD 486,000. Sangui used cash in operating acitivities of approximately USD 457,000 (2006 period: approximately USD 242,000). The company's accumulated deficit amounted to USD 22.3 million as of March 31, 2007.

Apart from the contribution margin generated from sales of its cosmetics and wound management products, operations in the first nine months of FY 2007 were financed by investments from several European investors in the amount of approximately USD 543,000. In accordance with US-GAAP the amount is shown as Foreign currency translation adjustments in the profit-and-loss statement and as Effect of exchange rate changes in the cash-flow statement respectively.

In the first nine months of its financial year 2008 (July 1, 2007 through March 31, 2008), Sangui BioTech International, Inc., generated hardly any sales. The company invested in identifying and establishing new sales opportunities in international markets, to wit Mexico and the Arab countries, as well as in the approval process of its Hemospray wound spray in accordance with European, Mexican and US regulations. Ensuing losses were financed by continued investments from several European investors.

05.06.2008

Company News

Experts confirm HEMO2SPRAY safety
Sangui submits milestone documentation to Notified Body

Witten, Germany, June 5, 2008 - As a part of the registration of its HEMO2SPRAY wound spray according to the CE standards of the European Union SanguiBioTech GmbH now submitted comprehensive documentation to the Notified Body. Among a broad array of requested documents, this important milestone includes the required independent expert opinions about the toxicological and virological status of the product.

The virological opinion analyses potential risk factors in the raw material and describes the production process with special emphasis on its ability to remove eventually existing virusses from the product or to inactivate the remainders. According to the opinion the high temperature treatment and micro-filtration stages of the production process provide a sufficient safety margin.

After a detailed appreciation of the therapeutical experiences the toxicological opinion concludes that "in view of the expected improvements of wound healing the use of HEMO2SPRAY is a positive element of wound management. Hemoglobin and its degradation products in the intended application form and quantities are safe for patients, staff and third persons. Subsequently, the benefit/risk ratio for HEMO2SPRAY is positive."

The next stage of the registration process consists mainly of the validation of the production process from the generation of the raw material to the end product."

28.05.2008

Company News

HemCon and Sangui joint press release:

HemCon Medical Technologies Leverages Sangui Technology to Expand its Wound Care Products Line

PORTLAND, Ore. - May 28, 2008 - HemCon Medical Technologies Inc. today announced it will use Witten, Germany-based SanguiBioTech GmbH's CHITOSKIN technology platform to help further innovations in hemostatic bandages and wound care dressings for the acute care market.

Under the terms of the agreement, HemCon will leverage Sangui's technology platform to enhance and expand its product offerings for surgical and wound care. HemCon developed the chitosan-based hemostatic HemCon® Bandages and ChitoFlex® dressings that are used by military and medical first responders as well as health care professionals around the globe.

"We explored a wide variety of technology platforms to add to our new surgical and wound care offerings and feel that the Sangui chitosan platform offers great opportunities to enhance our solutions," said John W. Morgan, president and CEO of HemCon. "We're committed to continuing our investment to develop new choices for medical professionals and consumers. This agreement is an important step forward in realizing the full potential of chitosan-based products."

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. Sangui BioTech International focuses on vascular and hemostasis products. The firm specializes in developing oxygen-carrying agents to treat blocked arteries, anemia or acute blood loss through SanguiBioTech GmbH.

"We are proud to enter into an agreement with HemCon and offer our chitosan platform to help innovate new surgical and wound care products," said Sangui Managing Director Hubertus Schmelz. "There is definitely a demand for products that can adapt to specific medical needs, especially as it relates to wound care."

HemCon retains exclusive worldwide market and distributing rights for products developed under this structured financial agreement. HemCon will submit developed products for U.S. approvals to the FDA, while Sangui will prepare documentation for registration in the European Union.

About HemCon Medical Technologies Inc.

HemCon Medical Technologies Inc., founded in 2001, develops, manufactures and markets innovative products and technologies to improve patient care and control infection. The flagship hemostatic HemCon dressings are used by military and civilian first responders as well as medical professionals in hospital, dental and clinical settings where rapid control of bleeding is of critical importance. In addition HemCon develops and licenses unique technology platforms and delivery systems for us in the cosmeceutical, wound care, and cardiovascular health markets. Synpart, a wholly-owned, European subsidiary of HemCon is a leading designer and manufacturer of general oral care products. HemCon corporate headquarters reside in Portland, Oregon with additional commercial operations Ireland; England; Germany and the Czech Republic. For more information, please visit www.hemcon.com.

About SanguiBioTech GmbH

SanguiBioTech GmbH is a wholly-owned subsidiary of Sangui BioTech International Inc. (www.pinksheets.com: SGBI). Established in 1995, the company focuses on improving the oxygen supply to the human body. The company has developed a range of products providing oxygen to the healthy as well as to the damaged skin and distributes medicosmetics as well as wound management products in Europe and other international markets. One of its core technologies is the patented Chitoskin technology range, a unique and multi purpose chitosan based wound dressing family.

20.05.2008

Company News

Sangui reports first actual order from Arab countries

Witten, Germany, May 20, 2008 - Future Health Est., based in Jeddah, Saudi Arabia, has now purchased an initial quantity of CHITOSKIN wound dressings, SanguiBioTech GmbH reports today. Future Health Est. is a distributor of various medical and other goods in Saudi Arabia.

Sangui Managing Director Hubertus Schmelz underlines that efforts to enter the Arabian markets had never been interrupted: "Over the past months we have been in constant contact with our Arabian partner. We are very glad that this cooperation now starts to come to fruition. Although there is no commitment yet with regard to future additional orders it is our aim in the medium term to establish an ongoing business relationship."

21.04.2008

Company News

Investors acquire share in Sangui BioTech GmbH

Witten, Germany, April 21, 2008 - A group of German investors is about to acquire up to 10% of the shares of SanguiBioTech GmbH, Witten, for a purchasing price of up to € 750,000. The acquisition will be effectuated by way of a capital increase which will be subscribed to by the investors. It will become effective after the investment sum will have been paid in on a Sangui account and after the capital increase will have been entered in the German register of commercial companies. The majority of those investors are already engaged as shareholders of Sangui BioTech International, Inc., and by subscribing to convertible promissory notes.

Hubertus Schmelz, Managing Director of SanguiBioTech GmbH, said: "We are glad that our investors show uninterrupted confidence in Sangui's future. Their thorough understanding of the long term perspective of our products and projects is highly appreciated. This renewed investment will mainly serve to finance ongoing business as well as special initiatives to promote further development, marketing and sales activities."

08.04.2008

Company News

Sangui BioTech International, Inc., reports sales increase, continued losses

Wolfgang Barnikol resigns from executive positions

Witten, Germany, April 8, 2008 - Sangui BioTech International, Inc., published its financial statements for its fiscal year ended June 30, 2006, on April 3, 2008. According to the report on form 10-KSB as filed with the SEC the company almost tripled its sales of cosmetics and wound management products, although from a low level. In FY 2006, Sangui yielded sales of approximately USD 137,000 and a Gross Profit of approximately USD 19,000. Due to the ongoing cost containment program operating expenses were down 25% to approximately USD 758,000. The company reports a net loss for the year of approximately USD 743,000. The resulting accumulated deficit amounts to approximately USD 21.8 million. Total shareholders' deficit as of June 30, 2006 stands at approximately USD 384,000. Net cash used in operating activities of approximately USD 283,000 was partially offset by cash inflows from financing activities in the amount of approximately USD 235,000.

According to the 10-KSB report these conditions raise substantial doubt about the Company's ability to continue as a going concern. In order for the Company to continue its operations at its existing levels, the Company will require significant additional funds. Therefore, the Company is dependent on funds raised through equity or debt offerings.

Preliminary unaudited figures for Sangui's fiscal year ended June 30, 2007, indicate that Sangui yielded sales in this period of approximately USD 373,000. An increase in operating expenses which is attributable to increased marketing and sales efforts is the main factor for the resulting net loss of approximately USD 704,000. The company strives to file its pending quarterly and annual reports for its 2007 and 2008 fiscal years over the next couple of months.

Cornerstones of Sangui's current business include sales of cosmetics and wound management products through different distribution partners in Germany and abroad. Sales in several Arab countries are subject to their registration in the respective countries. Sangui is not involved in these registration procedures and has no influence on them. At present, there is no reliable basis to predict when sales will start and which volumes may be generated. Negotiations about raising a substantial mezzanine loan were now discontinued as conditions appeared to be unfavorable for the company. Further business opportunities are largely dependent on the successful registration of Sangui's Hemospray wound spray. The company's current plans anticipate that the registration for sales in the European Union may be obtained in the course of calendar year 2008.

The company currently has two employees as well as consulting agreements with five persons in charge of management and development acitivities. In the course of the 2007 calendar year several European investors provided cash inflows to the company of more than EUR 0.6 million.

Wolfgang Barnikol resigns from executive positions

Professor Wolfgang Barnikol has declared to lay down his positions as President, Chief Executive Officer and Chief Financial Officer of Sangui BioTech International, Inc.. He will continue to serve as a Member of the Board of the company and contribute his scientific and medical expertise to further promote Sangui projects. The Board of Directors has agreed to appoint Thomas Striepe as interim CEO and Joachim Fleing as interim CFO of Sangui International. Both will serve in this position until the election of a new Board of Directors on the occasion of the planned shareholders' meeting. Operations of the company will continue to be directed by Hubertus Schmelz, the Managing Director of SanguiBioTech GmbH the Witten based wholly-owned subsidiary.

04.12.2007

Company News

Sangui partnership enters a new phase:

Second wound ambulance established in Monterrey

Monterrey, Mexico, and Witten, Germany, December 4, 2007 - Sangui Latino America and Sangui BioTech GmbH executives jointly opened another wound management ambulance in the center of Monterrey, Mexico, on the occasion of a three day working visit. Sangui BioTech GmbH Managing Director Hubertus Schmelz and Sangui Marketing Representative Renate Pentzien discussed the next steps of the successful cooperation of the two companies with the Mexican partners. An enlarged series of cosmetics presented by Renate Pentzien on this occasion met considerable interest.

State health authorities support approval and practical use of wound management products

Submitted were letters of the State Ministry of Health of the Mexican state of Tamaulipas. In those letters the health authorities underscore their support of both, the further wound management projects as well as the planned preclinical and clinical tests aiming at the approval of Sangui's blood additive. Starting early in 2008, clinical studies will be carried out at the General Hospital of Ciudad Victoria, Tamaulipas' capital, using Sangui's wound management products (SCABREMOVE for wound debridement, the HEMO2SPRAY wound spray and the CHITOSKIN wound pad) on another 30 patients suffering from chronic wounds. In charge of the studies will be specialist doctors at this hospital in cooperation with Sangui medical staff. It is being anticipated that the studies will be accomplished in the course of the first half of 2008.

According to additional information provided by Sangui Latino America, a health authority approval of the Sangui products as medical products will be available shortly after the successful accomplishment of this study. Moreover, Sangui Latino America indicated that the State of Tamaulipas intends to make comprehensive practical use of Sangui's products in hospitals and medical institutions under its responsibility.

Both companies appreciated this official commitment as the most important result of their cooperation so far. It underlines the succes of the therapeutic work carried out in the private ambulances, which completely yielded the expected healing results. According to the Mexican partners, a medical products approval by the Tamaulipas State Ministry will immediately put Sangui in the position to service not only the Mexican but also the entire Latin American market.

Mexico counts approximately 17 million diabetes II patients, the care and therapy of whom consumes more than 30% of the Mexican health budget - at a still increasing percentage. Other reasons for the occurrence of chronic wounds include ulcus cruris or amputations, all of which are eligible for treatments with Sangui products. Clinical data obtained in Mexico will be beneficial also for the EU approval process, which continues to be on schedule.

Definite planning starts for blood additive project

The Tamaulipas State Ministry has additionally declared its comprehensive support for the blood additive project including in particular the preclinical and clinical studies. Sangui Latino America and Sangui BioTech GmbH, therefore, have started definite planning aimed at the fastest and most efficient ways to carry out this key project. The respective planning how to produce the test substance needed for the preclinical testing has already been completed. Currently, the favourite option is to establish the production facility in the existing clean rooms of Sangui BioTech in Witten, Germany. The test design describing the toxicological as well as pharmacological tests of the preclinical phase will be written in close cooperation with the authorities in Ciudad Victoria. Starting immediately, test designs for possible clinical studies will be elaborated in mutual understanding of all parties involved. The target is to identify and weigh different possible indications including in particular heart attack and lung shock. It is the common understanding of the partners to look at a project start in the course of the first half of 2008.

The two companies in Germany and Mexico which are not affiliated legally have established a trustful partnership which now becomes increasingly closer.

Hubertus Schmelz underscores, therefore: "We are very satisfied with the course things in Mexico are now taking thanks to the energy of our partners. Their commitment, their willingness to invest and their determination are paramount examples for the industry. They allowed our wound management products to show in a large number of patients that they actually work the way we expected them to. Based on the test results obtained so far we expect that we will be able to accomplish the additional 30 patient study successfully and at short notice. The entailing official approval as medical products would give us access to important and large markets. And, we are particularly excited about the prospects for the blood additive – as this key venture of our company will enter definite planning and roll-out at last. We are more than grateful for our partners in Mexico. It is their strong commitment which makes all this fast progress happen."

The joint prospects are being confirmed by Sangui Latino America President Eduardo Mena: "In the past couple of months, we have been able to convince ourselves that Sangui's wound management products and concepts do keep what they promise. We are determined, therefore, to further extend our commitment and to take the necessary steps towards product approval in close accordance with the Tamaulipas authorities. Jointly also we shall proceed with the blood additive project, as we consider it a product which will eventually help treating severly ill patients and even save their lives. We are well aware of the financial requirements, but we are deeply convinced that this is an investment which will pay back."

22.10.2007

Company News

Medicoforum and Sangui part

EU HEMO2SPRAY authorization to be carried out by successful CHITOSKIN team

Witten, Germany, October 22, 2007 The contracts between SanguiBioTech GmbH and Hannover, Germany, based Medicoforum group have been concluded. Medicoforum group is no longer entrusted with services relating to the authorization of Sangui's HEMO2SPRAY wound spray product. Sangui will now once again rely on the team that successfully attained the EU authorization of its CHITOSKIN wound pads in 2006.

SanguiBioTech Managing Director Hubertus Schmelz said:
"The new development will give us more flexibility in coordinating the authorization as a medical product in Europe and America. Moreover, we are no longer obliged to share future revenues with the authorization partner. We feel that this move will considerably accelerate our efforts to introduce our innovative wound healing product in markets on both sides of the Atlantic."

21.09.2007

Company News

Sangui Announces Change of Auditor

Witten, Germany, September 21, 2007 - SanguiBioTech announced today that it has engaged Moore & Associates, Chartered as its registered independent accountants to perform its annual financial audits, including customary review of quarterly financial statements. Sangui had previously engaged HJ & Assoicates, LLC to perform such services.

The change in independent accountants did not result from any dissatisfaction with the quality of professional services rendered by HJ & Associates. Furthermore, there were no disagreements with HJ & Associates for the fiscal years ended June 30, 2004 or 2005, or for the interim period subsequent ending September 30, 2005, on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of HJ & Associates, would have caused them to make reference thereto in their reports on the financial statements for such periods.

06.08.2007

Company News

Products and Marketing Registration for the Arabian Markets on Schedule

Hemospray authorization to be underpinned by additional case studies

Witten, Germany, August 6, 2007 - In compliance with local laws applications have now been filed with the Ministry of the Economy of the United Arabian Emirates to sell Sangui cosmetics and wound management products in several Arabian markets. This includes the registration of the products as well as the required sales and marketing licences. It is being expected that the registration and licensing process will last several months according to a memorandum now communicated to SanguiBioTech GmbH by TYCOON Consulting (UK) Ltd. officials. The same sources pointed out that the successful registration is the main prerequisite of the planned participation and investment of TYCOON Venture Capital & Investment Ltd. in SanguiBioTech GmbH.

While wound healing experiences in Mexico are highly encouraging the European authorization process of Sangui's HEMO2SPRAY wound spray is being rescheduled. Aiming at an enhanced documentation exceeding the positive data obtained in Mexico additional case studies will be initiated in Europe. This new multifocus approach will delay the planned authorization but will result in underpinning the reliability of the medical findings.

23.05.2007

Company News

Arabian companies will start selling Sangui products in the course of next few months

Witten, Dubai, May 23, 2007 - Comprehensive marketing and distribution agreements to this effect have been signed between Sheikh Al Mudhareb, TYCOON Consulting (UK) Ltd. and SanguiBioTech GmbH after a series of presentations and in depth negotiations in Sharjah and Dubai. Products covered by the terms of the contracts include the whole range of Sangui's present and future cosmetics products as well as the range of medical products if and when certified for distribution in these markets. This refers in particular to Sangui's ChitoSkin wound pads based on bovine gelatine and the HemoSpray based on camel blood.

The agreements extend to a number of Arabian and Muslim countries including the United Arab Emirates, Saudi-Arabia, Kuwait, Oman, Yemen, Sudan, Jordan, Libya, Lebanon, Marocco, Malaysia, India and Turkey, granting the partner firms exclusive distribution rights for those markets. Discussions for similar agreements regarding Egypt are currently under way. Based on the current volume and pricing scheme which was discussed and agreed upon Sangui expects its cosmetics sales alone and based on the present portfolio to reach € 875.000 in 2007, € 1.750.000 in 2008 and € 3.500.000 in 2009. To this, any additional sales of future cosmetic products as well as medical products would be added.

It is understood by all parties concerned, that Sangui's unique products merit special marketing activities, and to this end the requisite TV and complimentary advertising strategies will be developed in collaboration with Sangui to ensure that a precise product message is conveyed to the customer.

"These marketing contracts follow exactly the road map of our initial agreement of Febr. 7th and open more or less the entire scope of Arabian markets for Sangui's products", Barbara Geisel, TYCOON Chairman, and Hubertus Schmelz, Sangui Managing Director, emphasized. "As the financial standing and marketing competence of our local partners is beyond any doubt, we are looking forward to a very exciting future."

Meanwhile, paperwork and discussions pertaining to the planned acquisition of 25% of SanguiBioTech GmbH by TYCOON VCI are on schedule.

17.04.2007

Company News

Sangui succeeds in replacing porcine raw material in Chitoskin wound pads

Witten, Germany, April 17, 2007 - SanguiBioTech GmbH has now received the first samples of Chitoskin wound pads using bovine instead of porcine gelatine as binding agent. Initial tests show that - as expected - the new formula produces identical wound healing properties as compared with the original product. Sangui had decided to develop this additional formula in view of potential hesitations in certain international markets with regard to products containing substances derived from pork.

In the same respect, Sangui has now started to investigate into the possibility of replacing porcine blood as raw material for the production of haemoglobin by camel blood. In February 2007, Sangui had announced that TYCOON Consulting (UK), Bristol, undertakes to market Sangui wound management products as well as cosmetics in several Arab countries.

12.04.2007

Company News

TYCOON Venture Capital & Investment Ltd. intends to finance Sangui blood additive and products

Participation in SanguiBioTech GmbH and loan volume of up to EUR 7.5 million

London and Witten, April 12, 2007 - TYCOON Venture Capital & Investment Ltd., London, UK, intends to acquire a stake of 25% in SanguiBioTech GmbH. As part of the planned agreement TYCOON Venture Capital & Investment is offering Sangui a mezzanine loan of up to EUR 7.5 million. The loan can be drawn in one initial tranche of one fourth of the total volume and a number of subsequent tranches which will be subject to Sangui's attaining certain performance milestones. A letter of intent to this effect was now signed. TYCOON will conclude its due diligence examination of the company in due course while both parties will negotiate the partnership and loan agreements and related legal documents.

Barbara Geisel, TYCOON Managing Director, explained: "We have thoroughly examined the properties and market potential of Sangui's existing product portfolio as well as the possible future blockbuster qualities of its haemoglobin polymer blood additive and we are excited to have the opportunity to participate in the highly promising prospects of this company. As a venture capitalist we are fully aware of the risks and opportunities pertaining to the development of such innovative pharmaceutical. We intend to be an active partner and are ready to support Sangui in the medium and long term."

"The cooperation with TYCOON gives Sangui leeway to speed up its business development," added Hubertus Schmelz, Managing Director of SanguiBioTech GmbH. "With this move we overcome a period of relative uncertainty and create a sound and potentially prosperous business. With a proven and still expandable product portfolio, with our strategic partners in Mexico, and with a reliable financing partner we are now in the position to set out for maximising Sangui's value creation."

In February 2007, Sangui had announced that TYCOON Consulting (UK), Bristol, a sister company of TYCOON Venture Capital & Investment undertakes to market Sangui cosmetics as well as wound management products in several Arab countries.

Sangui's potentially live saving blood additive consists of haemoglobin polymers. It provides vital oxygen supplies to places in the human body erythrocytes cannot reach for instance due to arterial sclerosis. Initial indication for this pharmaceutical will be lung-shock, a live-threatening collapse of the lung which causes immediate death in cases of stroke and numerous other diseases.

07.02.2007

Company News

Tycoon Consulting (UK) intends to market Sangui products in several Arab countries

Witten and Bristol, February 7, 2007. - Subsequent to an extended sales presentation held by Sangui management in Cairo, Egypt, in December, 2006, Tycoon Consulting (UK), Bristol, UK, now undertakes to market Sangui cosmetics in several Arab countries, including Saudi Arabia, the United Arabian Emirates, Kuwait, Bahrain, Jordan and Egypt. In an agreement to this effect, Tycoon was granted exclusive distribution rights for Sangui cosmetics for the region. Initial orders are expected to be placed with SanguiBioTech GmbH, Witten, Germany, in the course of the next weeks. Plans are to expand this cooperation to additional Sangui products such as wound management as well as to discuss further areas of partnership.

17.10.2006

Company News

Breakthrough for Sangui Oxygen Carriers

Sangui enters new era of its history and starts blood additive authorization process. Mexican partner takes the lead in promoting live-saving medical innovation

ERC Nano Med and SanguiBioTech sign comprehensive cooperation contract, Medicoforum in charge of project management

Witten, Germany, October 17, 2006 - ERC Nano Med S.A. de C.V. of Monterrey, Mexico, and SanguiBioTech GmbH, Witten, Germany, will jointly promote the FDA authorization of Sangui's artificial oxygen carriers as blood additive. An agreement to this effect was signed in Hamburg, Germany, tonight. Initial indication for this pharmaceutical will be lung-shock, a live-threatening collapse of the lung which causes immediate death in cases of stroke and numerous other diseases. Both parties agreed to entrust Medicoforum, Hanover, Germany, a clinical research group with special expertise in global authorization processes, with managing the project. The first steps include the preparation of the documentation which will be the basis for all further applications as well as the establishing of a production facility for hemoglobin polymers in Monterrey which will produce the test substance for the preclinical studies scheduled to start in 2007.

Under the terms of the agreement, ERC will arrange for the preclinical and clinical trials in Mexico and finance large parts of the authorization process, while Sangui contributes its know-how in the medical, biological and chemical fields. Medicoforum shall contribute their efforts partly in consideration of participating in the commercial benefits. ERC was granted the exclusive rights to market and sell future products resulting from this authorization in North, Middle and South America. The agreement contains no advance payments by either side. The financial backup will be provided by Banco Regional de Monterrey (Banregio), whose principal shareholders are also engaged in ERC.

"We are thrilled by the opportunities this project will offer to those participating and to patients all over the world. Not only are we looking at new means to save human lives, but we are also addressing a multi-billion dollar market," said ERC CEO Ing. Eduardo Martinez Mena. "We are deeply convinced that Sangui's approach to use hemoglobin polymers as blood additive for enhanced oxygen supply is superior and highly promising because it avoids the risks which other attempts had to submit to. We are determined to put this to the test. We take pride in underlining the strong economic and scientific position of the State of Nuevo Léon and its capital Monterrey by taking the lead in promoting this live-saving innovation."

Hubertus Schmelz, Managing Director of SanguiBioTech GmbH, pointed out: "Our firm belief in the benefits and the correctness of our concept has never ceased and has driven us forward for many years. It is to my great satisfaction that thanks to the cooperation with ERC we now have the opportunity to demonstrate its validity."

As reported yesterday, ERC and Sangui have also agreed to a large scale cooperation in the field of wound management. Moreover, ERC has purchased an initial quantity of Sangui PURE MO2ISTURE Cosmetics for distribution in Mexico.

16.10.2006

Company News

Sangui Wound Management Products Head for the Mexican Market
ERC Nano Med obtains exclusive distribution rights and starts authorization process

Witten, Germany, October 16, 2006 - ERC Nano Med S.A. de C.V., Monterrey, Mexico, has been granted exclusive distribution rights of wound management medical products developed and produced by SanguiBioTech GmbH, Witten, Germany, for the territory of Mexico. Distribution, Collaboration and Commercialisation Agreements to this effect were signed in Hamburg, Germany, over the weekend. ERC will cooperate with the Mexican Health Authorities in order to achieve the certification and registration of Sangui's CHITOSKIN wound pads as well as the HEMO2SPRAY wound spray. All related costs for tests, technical test protocols, certification and registration will be borne by ERC Nano Med. Sangui will provide the required products for testing, ample documentation as well as scientific and medical support as appropriate. Terms of delivery, marketing and sales are to be agreed upon in subsequent contracts. Tests will also include a wound cleaning gel recently developed by Sangui. Initial activities in view of the authorization are under way.

Under certain conditions, the Mexican Public Health Organisation is entitled to prescribe medical products prior to their certification. ERC will cooperate with the University of Monterrey, UDEM, and the Instituto Mexicano Del Seguro Social, IMSS, in establishing a network of 15 to 20 qualified wound management centres throughout Mexico. Trainings for the medical staff will be held by Sangui experts.

The cooperation is being accompanied and supported by Medicoforum GmbH, Hanover, Germany, who are in charge of the HEMO2SPRAY certification in Europe. Medicoforum is currently preparing a marketing plan for Mexico. Initial results indicate a total market of 4.3 million prescriptions per year, 60% of which may qualify for the use of Sangui wound management products.

ERC Nano Med is a division of ERC Electrónica, Robótica y Control S.A. de C.V. also based in Monterrey, Mexico.

13.09.2006

Company News

Sangui and Medicoforum group cooperate in HEMO2SPRAY wound spray certification and distribution

Witten, Germany, September 13, 2006 - SanguiBioTech GmbH, Witten, Germany, and Medicoforum GmbH, Hanover, Germany, will cooperate in completing the development of Sangui's HEMO2SPRAY wound spray in order to achieve a certified and marketable product. Moreover, both companies have now signed an agreement outlining the cornerstones of a future joint marketing and distribution approach. Based on a joint letter of intent of November 2005, Medicoforum had inquired into the efficiency and marketability of this wound spray with satisfactory results.

Under the terms of this agreement, Mediconomics, a sister company of Medicoforum will prepare all necessary documents and promote the required certification processes. Sangui will provide scientific and medical documentation and support and will oversee production and storage of the product including the related quality management in cooperation with a contract manufacturer. The cooperation is based on Sangui's German and global patent applications DE 10212 321 A1 and WO 03/077941 A1, respectively. According to the project plan a certification may be accomplished by mid 2007.

Medicoforum has been granted exclusive marketing and distribution rights for the EU countries and the USA. Sangui and Medicoforum are entitled to 50% each of the net proceeds from this cooperation. More details will be subject to subsequent contracts. Medicoforum has also obtained the right to identify additional industry partners interested in marketing the product in specific territories and enter into negotiations with them. According to Medicoforum industry partners in different countries have expressed their interest.

29.08.2006

Company News

PURE MO2ISTURE anti-aging cosmetics now for sale in Sangui's new internet shop

Witten, August 29, 2006 - Effective today, SanguiBioTech GmbH, has launched a proprietary web shop exclusively dedicated to selling its innovative PURE MO2ISTURE face and body cosmetics. PURE MO2ISTURE cosmetics utilize a genuinely developed nano formulation to bridge the horny layer of the skin and to provide enhanced oxygen supply to the skin tissue and capillary vessels. Oxygen is a major factor in the ongoing production of collagen in the human body and therefore key to the sustainable regeneration of the skin. Dermatological tests carried out by one of Germany's most renowned independent test institutes repeatedly showed skin elasticity improvements of up to 61%. The website contains ample documentation of the dermato-cosmetic background and the test results. Promotion will include advertising and editorial coverage in selected magazines as well as database marketing and direct mail activities.

The German language web shop can be accessed under the address http://www.puremoisture.de. Pages in English, Spanish and Korean are under preparation.

At the same time, demand for Sangui's cosmetics from distribution partners in Germany and international is encouraging. In July and August, the first two months of the current fiscal year (ending June 30, 2007) Sangui received firm orders worth more than € 60,000.

06.07.2006

Company News

German Forces test CHITOSKIN wound pads

Witten, Germany, July 6, 2006 - The German Army has been provided with three batches of CHITOSKIN wound pads. The Sangui products are now being thoroughly tested at several Bundeswehr locations. In particular, tests will include inquiries into the hemostyptic and anti-bacterial properties (as found in in vitro tests) of these Chitosan based wound dressings.

Sangui contacts with Bundeswehr medical staff date back to November, 2005, and were intensified on the occasion the 1st Miltranet symposium "Stop the Bleeding! Bleeding Management in Military Trauma Care" hosted by the Bundeswehr Central Hospital in Koblenz May 11-13, where the wound pads were presented by Sangui management.

03.07.2006

Company News

Medicoforum starts entering certification process of Sangui's HEMO2SPRAY wound spray

Witten and Hanover, July 3, 2006 - Medicoforum GmbH of Hanover, Germany, on a European scale active in medical products marketing and distribution has now successfully accomplished the preparatory phase of the certification process of Sangui's HEMO2SPRAY wound spray. According to the findings of the first phase, HEMO2SPRAY qualifies for a CE medical product certification. Medicoforum is now starting to enter the actual certification process.

Moreover, Medicoforum identified promising market potential for the product in Europe and the US. Large medical products companies active in the field of advanced wound management have shown significant interest in entering a marketing and distribution cooperation.

As had been announced in November, 2005, Medicoforum and SanguiBioTech GmbH cooperate under a contractual agreement, according to which Sangui has granted Medicoforum all pertinent rights for the certification on an exclusive basis. Medicoforum will bear all related cost. Both partners now intend to agree upon a subsequent sales and supply contract, which is aimed at the EU member states and additional territories.

Sangui's HEMO2SPRAY wound spray aims at healing chronic wounds. One of the characteristics of chronic wounds is a significant oxygen deficiency. HEMO2SPRAY, therefore, applies hemoglobin based artificial oxygen carriers to the wound bed, which then provide the cells with an additional and bio-compatible oxygen supply. The thin hemoglobin layer acts as a diffusion amplifier (micro-lung). Test treatments have shown significant effects: wounds that had been static for several months in spite of a range of conventional treatments healed completely within weeks. The bio-compatibility of this innovative technology results in a considerable improvement of oxygen supply to the wound.

30.06.2006

Company News

CHITOSKIN paper meets strong interest at European Wound Management Association Conference

Witten, Germany, June 30, 2006

At the 2006 European Wound Management Association Conference (Prague May 18 - 20), Professor Wolfgang Barnikol, M.D., Ph.D., introduced "Chitosan matrix pads. A new generation of wound dressings". This paper was held in a free paper session covering innovative wound management technologies and met noticeable interest with industry and medical attendants. Wolfgang Barnikol, Sangui BioTech International President and CEO, highlighted the many advantages offered by Chitosan based wound pads. Sangui's CHITOSKIN product is produced from natural Chitosan and porcine gelatine. The mixture of both substances is cross-linked and freeze-dried in a special process. The resulting sponge-like structure serves as a matrix for tissue growth supporting wound healing in all of its four phases. The chemical properties of CHITOSKIN, moreover, result in favourable effects such as hemostasic and anti-microbial results, macrophage stimulation, enhanced granulation and epithelization.

Gerd Mayer, Director Marketing with Karl Beese GmbH & Co., leading hospital supply vendor and Sangui's distribution partner, who also attended the conference explained: "We experienced a good response from conference participants and see significant market potential for Europe's first and only Chitosan based wound dressing."

11.04.2006

Company News

Sangui reports encouraging product sales
in Q2 and Q3

Witten, Germany, April 11, 2006 - SanguiBioTech GmbH recorded sales of approximately 54,000 USD and 44,000 USD in the second and third quarters of its fiscal year 2006 (ending June 30, 2006), respectively. Based on the current order book and talks with customers and distribution partners, sales for the fourth quarter are expected to be in the same magnitude. TV sales on channel HSE 24, in particular, now prove to be stable. Sangui's promotion partner has placed an additional order for Nano Body Care and initiated promising talks targeting the distribution of additional Sangui products on this channel, mainly the anti-aging face care.

Sales revenues at present cover about one third of ongoing costs. The company, therefore, is still dependent on bridge financing through issuance of shares and it maintains its strict cost management. Annual and quarterly reports will be released as soon as additional financing will be available.

Management looks at new sales potential resulting from the market launch of a proprietary cosmetics series under Sangui's PURE MO2ISTURE brand. In the field of wound management, the contacts with Hemcon Corp., Portland, Oregon, which had been reported in November, 2005, have reached a new stage. Technical data were exchanged in view of joint marketing and distribution activities outside the EU. Next steps will be considered in the course of the current quarter.

Negotiations with a leading German brand manufacturer aiming at new applications of Sangui's Chitosan technology in the consumer markets have entered a promising stadium. Subsequent to successful in vitro tests, additional in vivo tests are now underway; results are scheduled to come in during this quarter. Their particular target is the specific hemostyptic effect of Sangui's CHITOSKIN wound pad technology.

Also, subsequent to last year's presentation to German Air Force officials, Sangui has been invited to address the 1st Miltranet symposium hosted by Bundeswehr Central Hospital in Koblenz May 11-13. This international Congress focusses on the key issue "Stop the Bleeding! Bleeding Management in Military Trauma Care" (www.miltranet.org).

16.03.2006

Company News

Authorization of Sangui's HEMO2SPRAY to start in Turkey

Witten, Germany, March 16, 2006 - SanguiBioTech GmbH, Witten, Germany, has signed a sales and supply contract with Koneks Kaufheld Consulting, Istanbul, Turkey. In cooperation with local partners Koneks will carry out the authorization of Sangui's HEMO2SPRAY wound spray in the Turkish markets. HEMO2SPRAY is a hemoglobin based wound spray aiming at highly efficient treatment and sustainable healing of chronic wounds. Accomplishment of the authorization process is expected for 2007. All related costs will be borne by Koneks and its partners. Preliminary medical test treatments showed positive results. The agreement includes the option to extend the cooperation to other countries as far as the pertinent rights have not been granted by Sangui to other companies. Sangui is currently preparing production and delivery of the quantitites needed for the authorization process. The agreement expires after ten years with an option to further extend it. The Turkish partners are also interested in a sales cooperation concerning Sangui CHITOSKIN wound pads and Sangui cosmetics. The parties agreed to discuss details in this respect in the near future.

15.03.2006

Company News

Sangui Body Gel Sales Start in Argentina

Distributor Plans to Tackle Other South American Markets

Witten, Germany, March 15, 2006, Sangui's body gel is ready to enter the South American markets, Argentinian distributor ATS reports. 100 kg of the leading edge anti-cellulite formulation have been bottled. Launch marketing and sales are scheduled to start by the end of March, 2006. The product is offered under the PURE MO2ISTURE brand name. "Pre-marketing response was very promising", ATS Managing Director Jorge Kosanich says. "Consumers like the silky feel of the gel and appreciate the skin elasticity improvement. We feel confident that a successful start in Argentina will boost our plans to address entire South America and Mexico over the next year."

06.02.2006

Company News

Key hemoglobin related US and PCT patents granted to Sangui

Witten, Germany, February 6, 2006 - SanguiBioTech GmbH reports that two patents covering crucial parts of its hemoglobin and artificial oxygen carrier developments have now been granted by the European and US patent offices.

Effective January 11, 2006, the European Patent Office has granted European Patent No. 1 485 120 (International Application No. PCT/EP2003/002193). This patent labelled "Use of one or more natural or modified oxygen carriers (...) for externally treating open, in particular chronic wounds" guards Sangui's woundspray HaemO2Spray which is currently in the process of being authorized for sale throughout the European Union.

The United States Patent and Trademark Office has granted Patent No. US 6,956,025 covering Sangui's invention of "Mammalian haemoglobin compatible with blood plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen carriers (...)". This patent describes the pivotal technologies in producing artificial hemoglobin hyperpolymers which is the key development enabling production and use of Sangui's blood additive for medical purposes. "We had been granted similar PCT and German patents previously", professor Wolfgang Barnikol, Sangui Chairman and CEO said, "but we are particularly proud that the important US patent office confirms our innovation and protects our findings."

26.01.2006

Company News

CHITOSKIN export gains momentum

Biggest wound pad order so far destined for distribution in another EU member country

Witten, Germany, January 26, 2006 - Karl Beese GmbH & Co., leading medical products distributor headquartered in Barsbüttel, Germany, has placed an order with Sangui GmbH amounting to a total of 70.000 CHITOSKIN wound pads. The products are due to be delivered in two equal batches, the first one in February, the second one in July, 2006. The wound pads, currently available in germany and the Netherlands, will be sold to hospitals, physicians and other medical institutions in another member country of the European Union. A contract to this effect has been signed between Beese and a local partner company. This is the biggest single wound pad order received by Sangui so far. The order is part of Sangui's exclusive cooperation with Karl Beese GmbH & Co.

CHITOSKIN is a Sangui developped innovative wound pad with advanced wound healing properties. Sangui currently is in the process of investigating into additional appliances of this technology including new ways to treat fresh, bleeding wounds and extended sales opportunities including the consumer market. Talks with industry partners aiming at a business cooperation to this effect have been initiated.

23.01.2006

Company News

Kaufmann sells

Stocks of Sangui cosmetics completely sold, marketing partner asks for new supplies

Witten, January 23, 2006 - In three consecutive broadcasts, Sangui products proved to be hot selling on German TV shop channel HSE24, where famous actor Christine Kaufmann promoted them in her cosmetics program. As the stocks reserved for this channel are now completely sold, Sangui's marketing partner has ordered significant replenishments at short notice.

Sangui's cosmetics are based on a proprietary innovative nano emulsion as carrier which allows for an increased oxygen supply to the skin and an enhanced absorption of any active ingredients. In addition to the anti-aging face emulsion, to date, the range of available products includes an anti-cellulite body gel and a conditioner. Sangui's anti-cellulite-gel obtained premium results in tests with several groups of probands carried out by Dermatest, a renowned independent cosmetics research institute headquartered in Muenster, Germany. Skin elasticity improved over 40% in average in four weeks treatments and up to 61,5% in longer term treatments.

23.11.2005

Company News

Medicoforum to promote CE certification of Sangui's HEMO2SPRAY

Witten, November 23, 2005 - Medicoforum GmbH of Hanover, Germany, on a European scale active in marketing and distributing of medical products intends to promote the CE certification of Sangui's HEMO2SPRAY wound spray. In a first step, Medicoforum will check whether the product may indeed be certified as a medical product. This had been indicated by the German Federal Authority for Pharmaceuticals and Medical Products (Bundesamt für Arzneimittel und Medizinprodukte (BfArM)) in preliminary talks. At the same time, medicoforum will carry out market research regarding the sales potential in the member states of the EU and various other countries. The initital phase is limited to sixth months with Medicoforum being entitled to apply for an extension once. All pertinent rights serving this purpose have been granted exclusively to Medicoforum by Sangui. Medicoforum will bear all related cost.

If BfArM confirms that HEMO2SPRAY can be certified as a medical product and if the market research yields positive results, Medicoforum will enter the certification process. In this event both partners intend to agree upon a subsequent sales and supply contract, which is aimed at the EU member states and additional territories.

17.11.2005

Company News

Sangui innovative wound pad technology meets increasing attention

Hemcon and Sangui discuss opportunities for future joint activities - German Air Force takes a close look at Sangui's CHITOSKIN products

Witten, November 17, 2005 - Top management of Hemcon Inc., Portland, Oregon, including Hemcon President and CEO John W. Morgan, Vice President Research & Development Dr Simon McCarthy and Executive Vice President Sales & Marketing Bill Block met with Sangui President and CEO Professor Wolfgang Barnikol and SanguiBioTech GmbH Managing Director Hubertus Schmelz at the Medica trade show in Dusseldorf to exchange views about the international wound care markets. Both companies are active in the development of chitosan based wound pads and bandages. It was agreed to continue to exchange insights into advanced wound care technologies and further inquire into opportunities for joint activities in this and related fields. HemCon, Inc., founded in 2001, develops, manufactures, and markets innovative dressings and wound care technologies to control bleeding and infection resulting from trauma or surgery.

In the meantime, CHITOSKIN meets increasing attention in Germany also. On November 15, 2005, high ranking German Air Force Medical officials met with representatives of Cognis AG and SanguiBioTech GmbH at Air Force headquarters in Siegburg to discuss state of the art hemostyptic wound care. The talks focussed on Sangui's leading edge wound care products. The Air Force will now inquire further into this matter. Cognis AG is a global vendor of innovative specialty chemicals and nutrition components as well as one of the world's leading suppliers of Chitosan, the raw material for Sangui's CHITOSKIN and future CHITOSTYPT wound pads.

26.10.2005

Company News

Sangui reports flat sales in Q1, while significant orders were coming in

Witten, Germany, October 27, 2005 - While sales were flat in the first quarter of its fiscal year 2006, Sangui BioTech International, Inc., reports significant order intake. The order book in its cosmetics and wound management products stood at more than USD 72,000 as of September 30, 2005. There can be no assurance, however, that this upturn is indicative of sales for the rest of this fiscal year and beyond, company representatives emphasized. The company is still dependent on bridge financing through issuance of shares.

Current top customers include Karl Beese GmbH & Co. KG, leading German distributor of hospital supplies and medical products and distribution partner for CHITOSKIN, a German direct marketing company that will use Sangui products as part of a new line of cosmetic products, and Mercatura Biocosmetics AG, selling Sangui's anti-aging formulation as part of its "Wunderkind" range. The former contract with Mercatura which called for royalty payments by Mercatura has been abandoned in favour of a purchase agreement which requires Mercatura to pay against delivery of quantities purchased from Sangui. This is line with the agreements closed with other distributors and allows for better cash flow at comparable prices.

"An analysis of TV sales gets us a mixed picture," explains Hubertus Schmelz, Managing Director of SanguiBioTech GmbH. "RTL shop basically does not focus on cosmetics and its technical reach is limited. Sales in this channel, therefore, were below expectations. At QVC, sales were encouraging, but as part of a mixed product portfolio we have no influence on the positioning and advertising of our product." Sangui distribution partners have managed to position the Body Gel at HSE24, a third TV shop channel, specialising in cosmetics. "Highly encouraging, on the other hand, is the response from direct marketing companies", adds Hubertus Schmelz. "It is thrilling to find that now distribution partners call us, while a year ago we had to run after them."

Final import formalities are currently dealt with to ship an initial quantity of Sangui's Body Gel to Argentina, where a regional distributor will start sales in several South American countries under Sangui's "Pure Moisture by Renate Pentzien" brand before year end.

Centurion, Inc., of Seoul, South Korea, have indicated that both their testing and marketing activities for the Body Gel are well advanced and plans are to start selling in the christmas campaign. In addition, they are highly interested in Sanguis face treatment product based on the same technology and have received samples for testing. Sangui expects orders from Centurion for both products in the near future.

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. (www.pinksheets.com: SGBI).

Renate Pentzien, in charge of cosmetics marketing at Sangui's and the personality behind its cosmetics brand "Pure MO2isture by Renate Pentzien".

Under its own brand name for the first time, Sangui's Body Gel will be offered to South American customers starting December, 2005.

24.10.2005

Company News

CHITOSKIN met overwhelming response at European Wound Healing Congress

Witten, Germany, October 24, 2005 - The top event of the European wound care industry, this year's 9th European Wound Congress, held in Stuttgart, Germany, by the German Wound Healing Association DGfW, Sept. 14 - 17, 2005, was impressed by an unexpected highlight. Karl Beese GmbH Co. KG, leading German distributor of hospital supplies and medical products, presented Sangui's CHITOSKIN wound pads. The exposition in Beese's booth was boosted by the additional impact of Sangui President and CEO Professor Wolfgang Barnikol's much discussed lecture on CHITOSKIN's amazing wound healing capacities, which are underpinned by physiological theory and supported by ample documentation of numerous successful treatments.

"The response was overwhelming", emphasized Gerd Mayer, Beese's Marketing Director, "we outdid all the big shots. Order intake was strong and we had numerous requests from international distributors asking for distribution rights and deliveries for their respective markets." Beese are in the process of evaluating those requests but said they are close to sign contracts with partners in Italy, Switzerland and the Nordic countries.

Another Chitoskin lecture is scheduled for a congress "Standardization in modern wound management" to be held in Wiesbaden, Germany, October 28 and 29, 2005.

A new lot of wound pads is currently being produced and due to be shipped by the end of October.

Sangui is in the final stages of developing a new generation of wound pads with additional hemostyptic capacities.

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. (www.pinksheets.com: SGBI).

Caption: Presenting a wound healing innovation with amazing capacities on the 9th European Wound Congress are (from right to left) Alexander Beese, CEO of Karl Beese GmbH & Co. KG, Professor Wolfgang Barnikol, Sangui President and CEO, and Gerd Mayer, Beese Marketing Director.

25.05.2005

Company News

Centurion initiates authorization and subsequent marketing of Sangui's Body Gel in Korea, China,Taiwan and Japan

Witten, Germany, May 25, 2005 - SanguiBioTech GmbH, Witten, Germany, and Centurion, Inc., Seoul, Korea, signed a distributor agreement last week entitling Centurion to take all steps necessary to obtain regulatory clearance for Sangui's anti-cellulite body gel as a functional cosmetic, and subsequently to market and distribute the product in the markets in Korea, China, Taiwan and Japan. The authorization process is expected to last about six months. Under the terms of the contract Sangui will provide Centurion with the required quantities of the product against advance per unit payment by Centurion.

An initital quantity for the test and authorization phase has been shipped. Design and packaging options were discussed during the negotiations. The partners are considering to extend the cooperation to other Sangui cosmetic products.

Centurion, Inc., specializes in value added services for the pharmaceutical and medical products industries by establishing and arranging cooperations between research centers and corporations active in marketing and distributing products for the hospital markets in Asia with a special focus on Korea. Moreover, Centurion CEO In Kim and his team have a track record of successful introductions of third party products in these markets including the KFDA approval procedures. The company has established a comprehensive network of cooperation partners throughout Korea and Eastern Asia embracing renowned university research centers and industrial partners covering areas such as dermatology, immunology, vaccines, nano particles and chitosan.

In Kim founded Centurion after having served as CEO of MediLux, a company within the Hanmi Pharmaceuticals Group active in transfering the MIT developped Thermal Diffusion Probe technology to Asia. Prior to joining Hanmi he was managing international licensing and product authorization projects for a number of Korean companies. From 1980 through 1990 he served in the marketing and sales departments of Sandoz (Novartis) Korea. In Kim graduated from a top college of Seoul National University and obtained a pharmacist license in 1980.

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. (www.pinksheets.com: SGBI).

19.04.2005

Company News

Beese starts marketing activities for Sangui's CHITOSKIN wound pads
Sangui starts to develop additional hemostatic wound pad

17.03.2005

Company News

Joop - Wunderkind

16.03.2005

Company News

Sangui sells first quantity of anti-cellulite gel

14.03.2005

Company News

Sangui and BiologiQ negotiate wound pad sales in the Benelux countries

10.03.2005

Company News

Sangui obtains first product authorization
CHITOSKIN wound pad gets CE mark authorizing sales in European Union

08.03.2005

Company News

Sangui and Green Cross plan to evaluate options for a possible cooperation

28.02.2005

Company News